1. Home
  2. Products
  3. Gastrointestinal
  4. IDK® Pancreatic Elastase ELISA

IDK® Pancreatic Elastase ELISA

Item #: K6915 Category:


In Stock

Method: ELISA
Sample Type (Matrix): Stool
Sample Volume: 15 mg
Species: Human
Incubation time: 1h 10m
Standard Range: 2-72 ng/ml
Size: 96 wells
Regulatory Status: FDA Class 1 Exempt. For In Vitro Diagnostic Use. Health Canada Licensed.
Kit Manual: Download

Pancreatic elastase is a proteolytic enzyme produced in the pancreatic acinar cells and then secreted into the duodenum where it is converted into an active enzyme. Upon activation, pancreatic elastase degrades proteins and plays an important role in digestion. The stool concentration of pancreatic elastase reflects the secretory capacity of the pancreas, allowing for the diagnosis of exocrine pancreatic insufficiency (EPI). EPI is characterized by reduced pancreatic enzyme activity which inhibits digestion.

The IDK® Pancreatic Elastase ELISA is an enzyme immunoassay intended for the quantitative determination of human pancreatic elastase in stool. FDA Class 1 Exempt. For In Vitro Diagnostic Use. Health Canada Licensed.

The IDK® Pancreatic Elastase ELISA is compatible with our IDK Extract® Stool Sample Preparation System.


  • Diagnosis and exclusion of EPI in case of unexplained diarrhea, constipation, steatorrhea, flatulence, weight loss, upper abdominal pain, and food intolerances
  • Monitor exocrine pancreatic function in cystic fibrosis, diabetes mellitus, or chronic pancreatitis


  • Pancreatic elastase is not broken down during passage through the GI tract, making fecal pancreatic elastase an ideal marker for EPI.
  • Fecal pancreatic elastase is 5-6 fold more concentrated than in pancreatic juice.

If your lab is testing at high volumes, we have a variety of options for you:

Additional information

Weight35.5 oz
Dimensions6.5 × 10 × 4.5 in
Social media & sharing icons powered by UltimatelySocial

Become an IDK Insider!

Join our mailing list to receive the latest news and updates from Immundiagnostik, Inc.


You have Successfully Subscribed!